DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg - (New Product)

DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg - (New Product)
Product Description

Valpharma provides a wide range of products which inlcudes DILTIAZEM HCl S.R. CAPSULES 200 mg - 300 mg for the treatment of hypertension, angina pectoris and some types of arrhythmia.Diltiazem is a nondihydropyridines (non-DHP) calcium channel blocker used in the therapy and prophylaxis of coronary insufficiency, exertional angina, angina at rest, Prinzmetal vasospastic angina and post-infarct status, essential hypertension of mild and moderate grade.)

  • Posology: once daily
  • Dossier: available, including bioequivalence studies vs Mono-Tildiem LP (Sanofi Aventis, France)
  • CPP: available
  • Available for worldwide marketing authorization applications
  • Marketing authorization granted: Belgium, France, Germany, Italy, Luxemburg, Spain, The Netherlands, Tunisia
Please contact us for more information.

Valpharma Group

  • IT
  • 2015
    On CPHI since

Valpharma Group

  • IT
  • 2015
    On CPHI since

More Products from Valpharma Group (4)

  • GLICLAZIDE S.R.  TABLETS 30 mg   -   (New Product)

    Product GLICLAZIDE S.R. TABLETS 30 mg - (New Product)

    Valpharma provides a wide range of products which includes GLICLAZIDE S.R. TABLETS 30 mg for the therapy of maturity onset Diabetes Mellitus (non-insulin-dependant or Type II), where dietary management alone has been  insufficient.Gliclazide is an oral hypoglycemic used for the control of blood glucos...
  • MELATONIN S.R. TABLETS 2 mg (New product)

    Product MELATONIN S.R. TABLETS 2 mg (New product)

    Valpharma provides a wide range of pharmaceutical products among which  MELATONIN S.R TABLETS 2 mg (a product under development).Melatonin S.R. tablets 2 mg is indicated as monotherapy for the short-term treatment of primary insomnia characterized by difficulty in getting to sleep and in keeping t...
  • E.C. ESOMEPRAZOLE 20 mg and 40 mg capsules (Product under development)

    Product E.C. ESOMEPRAZOLE 20 mg and 40 mg capsules (Product under development)

    Gastro-resistant capsules indicated for the treatment of acid-reflux disorders.
  • I.R. APIXABAN 2,5 mg and 5 mg tablets (Product under development)

    Product I.R. APIXABAN 2,5 mg and 5 mg tablets (Product under development)

    Anticoagulant (blood thinner) that reduces blood clotting and reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.